Delenex completes its Management

Delenex announces the appointment of Thomas Jung, MD, as its Chief Medical Officer. (Sep 1, 2011)

Delenex extends its A round to CHF 30.2 million

Thomas Dyrberg from Novo A/S joins the Board of Directors (May 3, 2011)

Delenex Therapeutics Voted 4th Most Promising Young Biotech in Switzerland

in Swiss Equity Magazine's special Life Sciences issue. (Apr 7, 2011)